Novartis continues to ‘reimagine’ itself, as Alcon spin-off completed
The new standalone company is worth up to 28 billion Swiss francs.
Read More
Tag: Alcon
Novartis to spin off eye unit Alcon
Novartis has announced plans to spin off its eye-care unit Alcon into a standalone entity.
Read More
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
- Johnson & Johnson seeks EMA approval for teclistamab–daratumumab combination
- HUTCHMED begins phase 3 stage of pancreatic cancer trial
